{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:44Z","timestamp":1792783364089,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Natural Science Foundation of China","award":["82104307"],"award-info":[{"award-number":["82104307"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Hunan Province","award":["2024JJ4080"],"award-info":[{"award-number":["2024JJ4080"]}]},{"name":"Scientific Research Project of Hunan Provincial Health Commission","award":["B202313016776"],"award-info":[{"award-number":["B202313016776"]}]},{"name":"Talent Project established by Chinese Pharmaceutical Association Hospital Pharmacy Department","award":["CPA-Z05-ZC-2024-003"],"award-info":[{"award-number":["CPA-Z05-ZC-2024-003"]}],"id":[{"id":"https:\/\/ror.org\/023q20n38","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100014764","name":"China International Medical Foundation","doi-asserted-by":"publisher","award":["Z-2021-46-2503"],"award-info":[{"award-number":["Z-2021-46-2503"]}],"id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University.","id":[{"id":"https:\/\/ror.org\/053v2gh09","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Medical Research Project of Hunan Medical Association: Clinical Pharmacy Research Program Funded Project","award":["HMA202503014"],"award-info":[{"award-number":["HMA202503014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04808-z","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:47:54Z","timestamp":1791366474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1R expression and dermatological diseases: a mendelian randomization and real-world study"],"prefix":"10.1007","volume":"91","author":[{"given":"Xiangling","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"issue":"9548","key":"4808_CR1","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"D.J. Drucker, M.A. Nauck, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 368(9548), 1696\u20131705 (2006)","journal-title":"Lancet"},{"issue":"9645","key":"4808_CR2","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","volume":"372","author":"DJ Drucker","year":"2008","unstructured":"D.J. Drucker et al., Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 372(9645), 1240\u20131250 (2008)","journal-title":"Lancet"},{"issue":"9","key":"4808_CR3","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s00125-024-06142-3","volume":"67","author":"W Wang","year":"2024","unstructured":"W. Wang et al., Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial. Diabetologia. 67(9), 1783\u20131799 (2024)","journal-title":"Diabetologia"},{"issue":"9961","key":"4808_CR4","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1016\/S0140-6736(14)61335-0","volume":"384","author":"C Eng","year":"2014","unstructured":"C. Eng et al., Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 384(9961), 2228\u20132234 (2014)","journal-title":"Lancet"},{"issue":"1","key":"4808_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Z. Zheng et al., Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal. Transduct. Target. Ther. 9(1), 234 (2024)","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"4808_CR6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","volume":"20","author":"D Giugliano","year":"2021","unstructured":"D. Giugliano et al., GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc. Diabetol. 20(1), 189 (2021)","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"4808_CR7","first-page":"6","volume":"5","author":"Y Tu","year":"2025","unstructured":"Y. Tu, H. Yu, Research progress and future prospects of small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs). Metabolism Target. Organ. Damage. 5(1), 6 (2025)","journal-title":"Metabolism Target. Organ. Damage"},{"issue":"4","key":"4808_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.20517\/mtod.2025.152","volume":"5","author":"AV Piazzolla","year":"2025","unstructured":"A.V. Piazzolla, A. Napolitano, A. Mangia, Pharmacologic approach to metabolic dysfunction and related diseases: focus on liver aspects. Metabolism Target. Organ. Damage. 5(4), 67 (2025)","journal-title":"Metabolism Target. Organ. Damage"},{"issue":"4","key":"4808_CR9","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"J.J. Holst, The physiology of glucagon-like peptide 1. Physiol. Rev. 87(4), 1409\u20131439 (2007)","journal-title":"Physiol. Rev."},{"key":"4808_CR10","doi-asserted-by":"publisher","first-page":"721135","DOI":"10.3389\/fendo.2021.721135","volume":"12","author":"X Zhao","year":"2021","unstructured":"X. Zhao et al., GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front. Endocrinol. (Lausanne). 12, 721135 (2021)","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"4","key":"4808_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.36849\/JDD.8605","volume":"24","author":"S Daniel","year":"2025","unstructured":"S. Daniel et al., A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies. J. Drugs Dermatol. 24(4), 413\u2013415 (2025)","journal-title":"J. Drugs Dermatol."},{"issue":"6","key":"4808_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s00403-024-02969-3","volume":"316","author":"CE Salazar","year":"2024","unstructured":"C.E. Salazar et al., Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature. Arch. Dermatol. Res. 316(6), 248 (2024)","journal-title":"Arch. Dermatol. Res."},{"issue":"9","key":"4808_CR13","doi-asserted-by":"publisher","first-page":"869","DOI":"10.36849\/JDD.8926","volume":"24","author":"N Gupta","year":"2025","unstructured":"N. Gupta et al., Glucagon-Like Peptide-1 Receptor Agonists Reduce Surgeries and Hospitalizations in Hidradenitis Suppurativa: A Multicenter TriNetX Cohort Study. J. Drugs Dermatol. 24(9), 869\u2013874 (2025)","journal-title":"J. Drugs Dermatol."},{"issue":"1","key":"4808_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/bjd\/ljaf382","volume":"194","author":"A Svedbom","year":"2026","unstructured":"A. Svedbom, Potential additional benefits of glucagon-like peptide-1 receptor agonists in psoriasis. Br. J. Dermatol. 194(1), 5\u20136 (2026)","journal-title":"Br. J. Dermatol."},{"issue":"12","key":"4808_CR15","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1016\/j.jid.2025.08.045","volume":"145","author":"J Ghebrehiwet-Kuflom","year":"2025","unstructured":"J. Ghebrehiwet-Kuflom et al., GLP-1 Receptor Agonists as Emerging Modulators of Inflammation and Angiogenesis in Chronic Cutaneous Wound Healing. J. Invest. Dermatol. 145(12), 2981\u20132988 (2025)","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"4808_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.36849\/JDD.9448","volume":"25","author":"MN Fat","year":"2026","unstructured":"M.N. Fat, H.C. Johnson, A.S. Farberg, Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018\u20132024. J. Drugs Dermatol. 25(1), 11\u201316 (2026)","journal-title":"J. Drugs Dermatol."},{"issue":"1","key":"4808_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2337\/dc25-1822","volume":"49","author":"J Tong","year":"2026","unstructured":"J. Tong et al., Metabolic Improvement Mediates the Causal Relationship Between GLP-1 Receptor Agonists and Myocardial Infarction: A Mendelian Randomization and Mediation Analysis Study. Diabetes Care. 49(1), 171\u2013178 (2026)","journal-title":"Diabetes Care"},{"issue":"8","key":"4808_CR18","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1097\/JS9.0000000000001514","volume":"110","author":"Y Sun","year":"2024","unstructured":"Y. Sun et al., Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials. Int. J. Surg. 110(8), 4688\u20134694 (2024)","journal-title":"Int. J. Surg."},{"issue":"10","key":"4808_CR19","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41588-020-0684-4","volume":"52","author":"V Orr\u00f9","year":"2020","unstructured":"V. Orr\u00f9 et al., Complex genetic signatures in immune cells underlie autoimmunity and inform therapy. Nat. Genet. 52(10), 1036\u20131045 (2020)","journal-title":"Nat. Genet."},{"issue":"1","key":"4808_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s12916-024-03700-9","volume":"22","author":"D Gill","year":"2024","unstructured":"D. Gill et al., Common pitfalls in drug target Mendelian randomization and how to avoid them. BMC Med. 22(1), 473 (2024)","journal-title":"BMC Med."},{"issue":"1","key":"4808_CR21","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.1038\/s41467-024-50385-y","volume":"15","author":"Z Lin","year":"2024","unstructured":"Z. Lin, W. Pan, A robust cis-Mendelian randomization method with application to drug target discovery. Nat. Commun. 15(1), 6072 (2024)","journal-title":"Nat. Commun."},{"issue":"5","key":"4808_CR22","doi-asserted-by":"publisher","first-page":"e1004383","DOI":"10.1371\/journal.pgen.1004383","volume":"10","author":"C Giambartolomei","year":"2014","unstructured":"C. Giambartolomei et al., Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 10(5), e1004383 (2014)","journal-title":"PLoS Genet."},{"issue":"9","key":"4808_CR23","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.7150\/ijms.55421","volume":"18","author":"L Huang","year":"2021","unstructured":"L. Huang et al., Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System. Int. J. Med. Sci. 18(9), 1946\u20131952 (2021)","journal-title":"Int. J. Med. Sci."},{"key":"4808_CR24","doi-asserted-by":"publisher","first-page":"1159453","DOI":"10.3389\/fmed.2023.1159453","volume":"10","author":"M Ko","year":"2023","unstructured":"M. Ko, J.M. Oh, I.W. Kim, Drug repositioning prediction for psoriasis using the adverse event reporting database. Front. Med. (Lausanne). 10, 1159453 (2023)","journal-title":"Front. Med. (Lausanne)"},{"issue":"1","key":"4808_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12916-025-04031-z","volume":"23","author":"M Massy","year":"2025","unstructured":"M. Massy et al., Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data. BMC Med. 23(1), 203 (2025)","journal-title":"BMC Med."},{"issue":"11","key":"4808_CR26","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/acr.25400","volume":"76","author":"K Nguyen","year":"2024","unstructured":"K. Nguyen, B.D. Mitchell, A Guide to Understanding Mendelian Randomization Studies. Arthritis Care Res. (Hoboken). 76(11), 1451\u20131460 (2024)","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"4808_CR27","doi-asserted-by":"publisher","first-page":"155611","DOI":"10.1016\/j.metabol.2023.155611","volume":"146","author":"Y Zhao","year":"2023","unstructured":"Y. Zhao et al., Blood phytosterols in relation to cardiovascular diseases and mediating effects of blood lipids and hematological traits: a Mendelian randomization analysis. Metabolism. 146, 155611 (2023)","journal-title":"Metabolism"},{"issue":"5","key":"4808_CR28","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","volume":"32","author":"S Burgess","year":"2017","unstructured":"S. Burgess, S.G. Thompson, Interpreting findings from Mendelian randomization using the MR-Egger method. Eur. J. Epidemiol. 32(5), 377\u2013389 (2017)","journal-title":"Eur. J. Epidemiol."},{"issue":"5","key":"4808_CR29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","volume":"50","author":"M Verbanck","year":"2018","unstructured":"M. Verbanck et al., Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat. Genet. 50(5), 693\u2013698 (2018)","journal-title":"Nat. Genet."},{"issue":"1","key":"4808_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/EDE.0000000000000559","volume":"28","author":"S Burgess","year":"2017","unstructured":"S. Burgess et al., Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants. Epidemiology. 28(1), 30\u201342 (2017)","journal-title":"Epidemiology"},{"issue":"1","key":"4808_CR31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12916-024-03486-w","volume":"22","author":"Y Liang","year":"2024","unstructured":"Y. Liang et al., Do iron homeostasis biomarkers mediate the associations of liability to type 2 diabetes and glycemic traits in liver steatosis and cirrhosis: a two-step Mendelian randomization study. BMC Med. 22(1), 270 (2024)","journal-title":"BMC Med."},{"issue":"5","key":"4808_CR32","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.ajhg.2022.04.001","volume":"109","author":"V Zuber","year":"2022","unstructured":"V. Zuber et al., Combining evidence from Mendelian randomization and colocalization: Review and comparison of approaches. Am. J. Hum. Genet. 109(5), 767\u2013782 (2022)","journal-title":"Am. J. Hum. Genet."},{"issue":"3","key":"4808_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12016-023-08973-1","volume":"65","author":"HC Chen","year":"2023","unstructured":"H.C. Chen et al., Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches. Clin. Rev. Allergy Immunol. 65(3), 331\u2013353 (2023)","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"12","key":"4808_CR34","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1038\/jid.2010.213","volume":"130","author":"S L\u00e1szl\u00f3","year":"2010","unstructured":"S. L\u00e1szl\u00f3 et al., Generation of increased numbers of HLA-DR(high) IgG+ plasma cells in the peripheral blood of patients with bullous pemphigoid: NC16a-specific cells belong to the short-lived plasma blast population. J. Invest. Dermatol. 130(12), 2838\u20132841 (2010)","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"4808_CR35","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jdermsci.2017.11.014","volume":"89","author":"H Fang","year":"2018","unstructured":"H. Fang et al., Association of HLA class I and class II alleles with bullous pemphigoid in Chinese Hans. J. Dermatol. Sci. 89(3), 258\u2013262 (2018)","journal-title":"J. Dermatol. Sci."},{"key":"4808_CR36","doi-asserted-by":"publisher","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","volume":"182","author":"G Bendotti","year":"2022","unstructured":"G. Bendotti et al., The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists. Pharmacol. Res. 182, 106320 (2022)","journal-title":"Pharmacol. Res."},{"issue":"5","key":"4808_CR37","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/all.13376","volume":"73","author":"E de Graauw","year":"2018","unstructured":"de E. Graauw et al., Monocytes enhance neutrophil-induced blister formation in an ex vivo model of bullous pemphigoid. Allergy. 73(5), 1119\u20131130 (2018)","journal-title":"Allergy"},{"issue":"2","key":"4808_CR38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3109\/08916930008994081","volume":"32","author":"A Gonz\u00e1lez","year":"2000","unstructured":"A. Gonz\u00e1lez et al., Correlation between profile of circulating mononuclear cells and clinical manifestations in patients with pemphigus vulgaris. Autoimmunity. 32(2), 115\u2013128 (2000)","journal-title":"Autoimmunity"},{"issue":"3","key":"4808_CR39","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jid.2020.07.015","volume":"141","author":"A Oktem","year":"2021","unstructured":"A. Oktem et al., Clinical Relevance of Polymorphonuclear Myeloid-Derived Suppressor Cells in Autoimmune-Blistering Disorders Pemphigus Vulgaris and Bullous Pemphigoid. J. Invest. Dermatol. 141(3), 672\u2013675e1 (2021)","journal-title":"J. Invest. Dermatol."},{"issue":"12","key":"4808_CR40","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1016\/j.jid.2021.05.015","volume":"141","author":"O Varpuluoma","year":"2021","unstructured":"O. Varpuluoma et al., GLP-1 Analogs and SGLT2 Inhibitors Do Not Increase Risk of Bullous Pemphigoid. J. Invest. Dermatol. 141(12), 2969\u20132972e1 (2021)","journal-title":"J. Invest. Dermatol."},{"issue":"12","key":"4808_CR41","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/ggi.13799","volume":"19","author":"G Fukuda","year":"2019","unstructured":"G. Fukuda et al., Dulaglutide-related bullous pemphigoid in a patient with type 2 diabetes: A case report. Geriatr. Gerontol. Int. 19(12), 1289\u20131290 (2019)","journal-title":"Geriatr. Gerontol. Int."},{"issue":"5","key":"4808_CR42","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.12788\/cutis.0262","volume":"107","author":"MK Collins","year":"2021","unstructured":"M.K. Collins et al., Bullous Pemphigoid Triggered by Liraglutide. Cutis. 107(5), E9\u2013e11 (2021)","journal-title":"Cutis"},{"issue":"9","key":"4808_CR43","doi-asserted-by":"publisher","first-page":"e5374","DOI":"10.1590\/1414-431x20165374","volume":"49","author":"J Lu","year":"2016","unstructured":"J. Lu et al., CD19\u2009+\u2009B cell subsets in the peripheral blood and skin lesions of psoriasis patients and their correlations with disease severity. Braz J. Med. Biol. Res. 49(9), e5374 (2016)","journal-title":"Braz J. Med. Biol. Res."},{"key":"4808_CR44","doi-asserted-by":"publisher","first-page":"103414","DOI":"10.1016\/j.jaut.2025.103414","volume":"153","author":"Y Yang","year":"2025","unstructured":"Y. Yang et al., Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agents in autoimmune diseases. J. Autoimmun. 153, 103414 (2025)","journal-title":"J. Autoimmun."},{"issue":"3","key":"4808_CR45","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","volume":"33","author":"L Lin","year":"2022","unstructured":"L. Lin et al., Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. J. Dermatolog Treat. 33(3), 1428\u20131434 (2022)","journal-title":"J. Dermatolog Treat."},{"issue":"6","key":"4808_CR46","doi-asserted-by":"publisher","first-page":"e70983","DOI":"10.1002\/cns.70983","volume":"32","author":"X Chen","year":"2026","unstructured":"X. Chen et al., Integrating Pharmacovigilance Data Mining and Mendelian Randomization to Identify Risk Profiles and Causal Targets of Opioid-Induced Delirium. CNS Neurosci. Ther. 32(6), e70983 (2026)","journal-title":"CNS Neurosci. Ther."},{"key":"4808_CR47","doi-asserted-by":"publisher","first-page":"1782901","DOI":"10.3389\/fimmu.2026.1782901","volume":"17","author":"C Ke","year":"2026","unstructured":"C. Ke et al., Neuro-immune interactions in urticaria:a pruritus-centric dissection. Front. Immunol. 17, 1782901 (2026)","journal-title":"Front. Immunol."},{"key":"4808_CR48","doi-asserted-by":"crossref","unstructured":"T. Zuberbier et al., Insights into Pathogenesis of Chronic Spontaneous Urticaria. Br. J. Dermatol. 15, ljag277 (2026 )","DOI":"10.1093\/bjd\/ljag277"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04808-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04808-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04808-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:47:57Z","timestamp":1791366477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04808-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4808"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04808-z","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Clinical trial number: not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"334"}}